Nepexto: Uses, Dosage & Side Effects

What Is Nepexto and What Is It Used For?

Nepexto contains the active substance etanercept, a dimeric fusion protein produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. Etanercept consists of two copies of the extracellular ligand-binding domain of the human 75-kilodalton (p75) tumor necrosis factor receptor (TNFR2) linked to the Fc portion of human immunoglobulin G1 (IgG1). This unique molecular structure allows etanercept to function as a soluble decoy receptor, binding to circulating TNF-alpha and TNF-beta (lymphotoxin-alpha) molecules with high affinity and specificity, thereby preventing these pro-inflammatory cytokines from engaging with their cell-surface receptors and triggering downstream inflammatory cascades.

Tumor necrosis factor-alpha is one of the most important cytokines in the pathogenesis of autoimmune and chronic inflammatory diseases. Under normal physiological conditions, TNF-alpha plays essential roles in host defense against infections, immune surveillance, and tissue homeostasis. However, in autoimmune conditions such as rheumatoid arthritis, psoriasis, and spondyloarthritis, the immune system produces excessive amounts of TNF-alpha, leading to a self-sustaining cycle of inflammation. In rheumatoid arthritis, elevated TNF-alpha levels in the synovial joint lining stimulate fibroblast-like synoviocytes and macrophages, promoting the release of additional pro-inflammatory cytokines (interleukin-1, interleukin-6), matrix metalloproteinases, and receptor activator of nuclear factor kappa-B ligand (RANKL), which collectively drive synovial inflammation, cartilage destruction, and bone erosion.

By neutralizing excess TNF-alpha before it can bind to cell-surface receptors, etanercept interrupts this inflammatory cascade at a critical upstream point. This mechanism results in reduced joint swelling and tenderness, decreased production of acute-phase reactants (C-reactive protein, erythrocyte sedimentation rate), inhibition of bone erosion progression, and improved physical function and quality of life. In psoriasis, TNF-alpha blockade reduces keratinocyte proliferation and immune cell infiltration in the skin, leading to clearing of plaques and restoration of normal skin architecture.

Nepexto is a biosimilar medicine, meaning it has been developed to be highly similar to an already authorized biological medicine called Enbrel (the reference product), which has been used clinically since 1998. Biosimilars undergo a comprehensive regulatory evaluation program that includes extensive analytical characterization (physicochemical properties, biological activity, purity, and potency), nonclinical pharmacology and toxicology studies, and clinical pharmacokinetic, efficacy, and safety studies. The European Medicines Agency (EMA) approved Nepexto in May 2020 after reviewing the totality of evidence demonstrating no clinically meaningful differences between Nepexto and Enbrel in terms of quality, safety, efficacy, and immunogenicity.

Nepexto is authorized for the treatment of the following conditions in the European Union:

• Rheumatoid arthritis (RA): In combination with methotrexate, for the treatment of moderate to severe active RA in adults when the response to disease-modifying antirheumatic drugs (DMARDs) including methotrexate has been inadequate. Nepexto can also be used as monotherapy in cases of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. It has also been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.
• Psoriatic arthritis (PsA): For the treatment of active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.
• Axial spondyloarthritis: Including ankylosing spondylitis (AS) for the treatment of severe active disease in adults who have had an inadequate response to conventional therapy, and non-radiographic axial spondyloarthritis with objective signs of inflammation (elevated CRP and/or MRI evidence) in adults who have had an inadequate response to NSAIDs.
• Plaque psoriasis: For the treatment of moderate to severe plaque psoriasis in adults who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate, or psoralen combined with ultraviolet A (PUVA).
• Pediatric plaque psoriasis: For the treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapy.
• Juvenile idiopathic arthritis (JIA): For the treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or proved intolerant of, methotrexate; and for psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or proved intolerant of, methotrexate; and for enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or proved intolerant of, conventional therapy.

What Should You Know Before Taking Nepexto?

Contraindications

Nepexto must not be used in certain clinical situations where the risks clearly outweigh the potential benefits. These absolute contraindications are based on extensive clinical experience with etanercept accumulated over more than two decades of use worldwide. The most critical contraindication is sepsis or risk of sepsis, as TNF-alpha plays an essential role in the body's defense against bacterial infections, and blocking it during active systemic infection can lead to rapid clinical deterioration and death. Clinical trials specifically excluded patients with sepsis, and post-marketing surveillance has confirmed that initiating anti-TNF therapy during sepsis is associated with increased mortality.

Nepexto is also contraindicated in patients with active infections, including chronic or localized infections such as tuberculosis, regardless of the site of infection. The immune-suppressive effects of TNF-alpha blockade can allow previously controlled infections to reactivate or worsen. Additionally, hypersensitivity to etanercept or to any of the excipients is an absolute contraindication. Hypersensitivity reactions, though rare, have included anaphylaxis and angioedema in post-marketing reports.

Warnings and Precautions

Several important warnings and precautions apply to Nepexto therapy, and prescribers must carefully evaluate each patient's risk profile before initiating treatment. The most significant concern is the increased risk of serious infections. In controlled portions of clinical trials, the rate of serious infections in etanercept-treated patients was approximately 1.4% compared with 0.7% for placebo. These serious infections have included pneumonia, cellulitis, septic arthritis, bacteremia, and rare cases of opportunistic infections including invasive fungal infections (histoplasmosis, coccidioidomycosis, aspergillosis), parasitic infections (listeriosis), and atypical mycobacterial infections.

Tuberculosis (TB) is of particular concern. Patients must be evaluated for both active and latent tuberculosis before starting Nepexto. This evaluation should include a detailed medical history, appropriate screening tests (tuberculin skin test or interferon-gamma release assay such as QuantiFERON-TB Gold), and chest imaging if indicated. If latent TB is diagnosed, appropriate anti-tuberculosis prophylaxis must be initiated before starting Nepexto, in accordance with local medical guidelines. Patients should be monitored closely for signs and symptoms of active TB throughout treatment, even if the initial TB screening was negative, because false-negative results can occur, particularly in immunocompromised patients.

Hepatitis B virus (HBV) reactivation has been reported in patients who are chronic carriers of HBV and are receiving anti-TNF therapies. Patients should be tested for HBV before starting treatment. Carriers of HBV should be closely monitored throughout treatment and for several months after discontinuation. If HBV reactivation occurs, Nepexto should be stopped and effective antiviral therapy with appropriate supportive care should be initiated.

There have been rare post-marketing reports of new-onset or worsening congestive heart failure (CHF) in patients receiving etanercept. Two large randomized controlled trials of etanercept in heart failure were terminated early due to lack of efficacy. While etanercept was not associated with increased mortality in these trials, caution is recommended in patients with pre-existing heart failure. Nepexto should not be used in patients with moderate to severe heart failure (NYHA class III or IV).

Rare cases of demyelinating disorders of the central nervous system (CNS), including multiple sclerosis, optic neuritis, and transverse myelitis, have been reported in patients receiving anti-TNF agents. Peripheral demyelinating events including Guillain-Barré syndrome have also been reported. Nepexto should be used with caution in patients with pre-existing or recent onset of demyelinating disorders, and treatment should be discontinued if such a condition develops.

Pregnancy and Breastfeeding

There are limited data on the use of etanercept in pregnant women. Animal reproduction studies with etanercept have not demonstrated harm to the fetus; however, because animal studies are not always predictive of human response, Nepexto is not recommended during pregnancy unless clearly necessary. Women of childbearing potential should be advised to use adequate contraception during treatment and for at least three weeks after the last dose of Nepexto.

Etanercept has been shown to cross the placental barrier, and etanercept levels have been detected in umbilical cord blood of neonates whose mothers received etanercept during pregnancy. The clinical significance of this finding is not fully established, but neonates exposed to etanercept in utero may have an increased risk of infection. Administration of live vaccines to infants exposed to etanercept in utero is not recommended for the first 16 weeks after the mother's last dose.

Limited published data indicate that etanercept is excreted in human breast milk at very low concentrations. Because etanercept is a large protein molecule that would be expected to be degraded in the infant's gastrointestinal tract, it is not anticipated to affect a breastfed infant. Nevertheless, a decision should be made whether to discontinue breastfeeding or to discontinue Nepexto therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.

How Does Nepexto Interact with Other Drugs?

Drug interactions with etanercept are primarily related to its immunosuppressive mechanism of action rather than traditional pharmacokinetic interactions. Because etanercept is a large protein molecule that is metabolized through protein catabolism (proteolytic degradation) rather than through hepatic cytochrome P450 enzymes, it does not interact with drugs that are metabolized by, or that inhibit or induce, CYP450 enzymes. This means that the traditional drug interaction concerns associated with small-molecule drugs do not generally apply to etanercept.

However, combining etanercept with other immunosuppressive biological agents creates additive immunosuppression that can significantly increase the risk of serious infections without providing additional therapeutic benefit. This principle underlies the most important drug interaction warnings for Nepexto. Clinical studies and post-marketing experience have clearly established that certain combinations should be avoided.

Major Interactions

Safe Combinations

Nepexto is commonly and safely used in combination with several conventional medications. In fact, the combination of etanercept with methotrexate is one of the most well-studied and effective treatment strategies for rheumatoid arthritis, and the pivotal TEMPO trial demonstrated that the combination of etanercept plus methotrexate was superior to either agent alone in reducing disease activity, preventing radiographic progression, and improving physical function.

Patients should always inform their physician about all medications, supplements, and herbal products they are taking before starting Nepexto. Although traditional pharmacokinetic interactions are not expected, the overall immunosuppressive burden of a patient's medication regimen must be considered when assessing infection risk.

What Is the Correct Dosage of Nepexto?

Nepexto treatment should be initiated and supervised by a specialist physician experienced in the diagnosis and treatment of the conditions for which etanercept is indicated. This includes rheumatologists, dermatologists, or pediatric rheumatologists as appropriate. The dosing of Nepexto follows well-established protocols developed through extensive clinical trial experience with etanercept over more than 25 years.

Adults

Children and Adolescents

Elderly Patients

No dose adjustment is required for elderly patients (age 65 years and older). The same dose and dosing frequency apply as for younger adult patients. However, elderly patients may be at higher risk for infections due to age-related decline in immune function, and closer monitoring during treatment is advisable. The incidence of infections and malignancies is generally higher in the elderly population, so the overall benefit-risk balance should be carefully considered.

Missed Dose

If you miss a dose of Nepexto, you should take it as soon as you remember. If it is almost time for your next scheduled dose (within 3–4 days), skip the missed dose and return to your regular dosing schedule. Do not take a double dose to make up for a missed injection. Maintaining a consistent weekly schedule is important for optimal treatment outcomes. Many patients find it helpful to set a reminder or choose a specific day of the week for their injection to help maintain adherence.

Overdose

No dose-limiting toxicities have been observed in clinical trials with etanercept. Single doses of up to 60 mg/m² have been administered intravenously to healthy volunteers without evidence of dose-limiting toxicity. The maximum tolerated dose of etanercept has not been established. There is no known specific antidote for etanercept overdose. In the event of an overdose, the patient should be monitored for signs and symptoms of adverse reactions, and appropriate supportive treatment should be instituted as necessary. Hemodialysis and peritoneal dialysis are not expected to be effective for etanercept removal due to its large molecular weight (approximately 150 kDa).

What Are the Side Effects of Nepexto?

Like all medicines, Nepexto can cause side effects, although not everybody gets them. The safety profile of etanercept has been extensively characterized through controlled clinical trials involving thousands of patients, long-term extension studies of up to 10 years, and post-marketing surveillance spanning more than two decades of global use. The biosimilar development program for Nepexto confirmed that its safety profile is consistent with that of the reference product Enbrel.

Side effects are classified below according to their frequency of occurrence, based on the following convention used by the European Medicines Agency: Very common (may affect more than 1 in 10 people), Common (may affect up to 1 in 10 people), Uncommon (may affect up to 1 in 100 people), and Rare (may affect up to 1 in 1,000 people).

Injection site reactions are the most frequently reported adverse events with etanercept. They typically occur within the first month of treatment and tend to decrease in frequency with continued use. Most injection site reactions are mild to moderate and resolve within 3–5 days without treatment. Rotating injection sites and allowing the pen to reach room temperature before injection can help reduce the incidence and severity of these reactions.

The overall rate of serious infections in controlled clinical trials was approximately 1.4% in etanercept-treated patients compared with 0.7% in placebo-treated patients. The most common serious infections include pneumonia, cellulitis, and septic arthritis. Patients on concomitant immunosuppressive therapy (particularly methotrexate and corticosteroids) and those with comorbid conditions such as diabetes, chronic lung disease, or advanced age are at higher risk for serious infections.

Malignancies have been reported in patients receiving anti-TNF therapies. In controlled portions of clinical trials of all anti-TNF agents, more cases of lymphoma were observed in patients receiving anti-TNF therapy compared with control patients. However, these patients had long-standing, highly active disease and had received prior and/or concomitant immunosuppressive therapies, which are themselves known risk factors for lymphoma. The overall malignancy rate in etanercept-treated patients in clinical trials was similar to that expected in the general population, and large observational studies have not demonstrated a significantly increased risk of solid cancers with etanercept use.

How Should You Store Nepexto?

Proper storage of Nepexto is essential to maintain the stability, potency, and safety of the medication. As a biological product containing a protein molecule, etanercept is sensitive to temperature extremes, light exposure, and physical agitation. Improper storage can lead to protein degradation, aggregation, or denaturation, which may reduce efficacy and potentially increase the risk of immunogenicity (formation of anti-drug antibodies).

The primary storage requirement is refrigeration at 2–8°C (36–46°F). The pre-filled pen should be stored in the original carton to protect it from light. Do not store Nepexto in the door of the refrigerator, where temperature fluctuations are greater; instead, place it in the main body of the refrigerator. Do not freeze Nepexto. If a pen has been accidentally frozen, it must be discarded even if it has subsequently thawed, as freeze-thaw cycles can damage the protein structure.

For convenience, a single Nepexto pre-filled pen may be stored at room temperature (up to 25°C / 77°F) for a maximum period of four weeks. Once removed from the refrigerator for room-temperature storage, the new expiration date (four weeks from removal) should be noted, and the pen should not be returned to the refrigerator. If the pen is not used within the four-week room-temperature period, it should be discarded. This room-temperature storage option is particularly useful for patients who travel or who prefer to keep a pen readily accessible for their scheduled injection day.

Before injection, visually inspect the solution through the viewing window of the pre-filled pen. The solution should be clear to slightly opalescent, colorless to slightly yellow, and practically free of visible particles. If the solution is cloudy, discolored, or contains visible particles, do not use the pen. Do not shake the pre-filled pen vigorously, as this can cause protein aggregation.

Keep Nepexto out of the sight and reach of children. Do not use the medicine after the expiration date stated on the carton and pre-filled pen label. Dispose of used pre-filled pens in a sharps disposal container in accordance with local regulations. Do not dispose of pens in household waste.

What Does Nepexto Contain?

Each Nepexto 50 mg pre-filled pen contains 50 mg of etanercept in 1.0 mL of solution for injection. Etanercept is the active pharmaceutical ingredient and is a dimeric fusion protein with a molecular weight of approximately 150 kDa, produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. The protein consists of two copies of the extracellular ligand-binding domain of the human p75 TNF receptor (TNFR2) fused to the Fc portion of human IgG1.

The excipients (inactive ingredients) in Nepexto serve important roles in maintaining the stability, solubility, and proper pH of the etanercept protein in solution:

• Sucrose: Acts as a stabilizer to protect the protein from denaturation during storage and temperature changes. It helps maintain the three-dimensional structure of etanercept, which is essential for its biological activity.
• Sodium chloride: Provides isotonicity to the solution, making it compatible with subcutaneous tissue and reducing pain upon injection.
• L-arginine hydrochloride: Functions as a stabilizer and solubilizer, helping to prevent protein aggregation.
• Sodium dihydrogen phosphate monohydrate: Part of the phosphate buffer system that maintains the solution at an optimal pH for protein stability.
• Disodium hydrogen phosphate dihydrate: The complementary component of the phosphate buffer system.
• Water for injections: The solvent for the formulation.

Nepexto does not contain any preservatives. The solution is formulated at a pH of approximately 6.3, which is optimal for etanercept stability. The pre-filled pen is designed for single use only and is equipped with an automatic needle guard that covers the needle after injection to prevent needlestick injuries.

Nepexto does not contain latex in the needle cap of the pre-filled pen. This is important for patients with known latex allergies, as some older prefilled syringe designs used latex components in the needle shield.